Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.

Ann Rheum Dis · 2023 · PMC9811099 · PMID 36137735

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

8 The exploratory nature and the lack of statistical evidence (ie, nominally significant p values) of a treatment by history of ASCVD interaction limits our conclusions on this subgroup analysis.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.